Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR448501 in relapsed/refractory B-cell non-Hodgkin lymphoma
NCT06392477Phase 1Recruiting
- Sponsor
- Sanofi
- Start
- Jul 2024
- Primary completion
- Jan 2028
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of dr-0201 in B-cell non-Hodgkin lymphoma, sponsored by Sanofi. Primary endpoints: Treatment-Emergent Adverse Event and Potential Pharmacologically Optimized Dose/Regimen. Started Jul 2024; status: recruiting.
02
Drugs
dr-0201
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06392477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06392477.